Neuroendocrine differentiation as a treatment target in prostate cancer
Cedric Pobel, MD, Gustave Roussy, Villejuif, France, describes findings regarding abiraterone in prostate cancer, confirming the absence of a biomarker to predict patient benefit, suggesting universal applicability. Additionally, neuroendocrine differentiation was observed in a subset of patients, linked to a more aggressive disease course. This highlights the need for intensified treatment strategies for these patients, such as antibody-drug conjugates, T-cell engagers, or bispecific antibodies. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
